(0.11%) 5 254.35 points
(0.12%) 39 807 points
(-0.12%) 16 379 points
(2.05%) $83.02
(1.63%) $1.746
(1.30%) $2 241.40
(0.97%) $24.99
(1.32%) $921.75
(0.39%) $0.927
(0.80%) $10.85
(0.13%) $0.792
(0.13%) $92.56
Live Chart Being Loaded With Signals
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis...
Stats | |
---|---|
Today's Volume | 283 020 |
Average Volume | 125 355 |
Market Cap | 43.28M |
EPS | $0 ( 2024-03-14 ) |
Next earnings date | ( $-0.240 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.130 |
ATR14 | $0.0230 (0.75%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-01 | Zeronda Tyler | Buy | 62 500 | Common Stock |
2024-01-02 | Zeronda Tyler | Sell | 93 | Common Stock |
2024-01-01 | Zeronda Tyler | Buy | 62 500 | Stock Option (right to buy) |
2024-01-01 | Stuart Iain | Buy | 62 500 | Common Stock |
2024-01-02 | Stuart Iain | Sell | 157 | Common Stock |
INSIDER POWER |
---|
-56.54 |
Last 99 transactions |
Buy: 3 356 313 | Sell: 7 912 153 |
Volume Correlation
VYNE Therapeutics Inc. Correlation
10 Most Positive Correlations | |
---|---|
ALBO | 0.962 |
CMPI | 0.962 |
OCSL | 0.934 |
PALT | 0.913 |
IRMD | 0.911 |
PLRX | 0.91 |
MLAC | 0.905 |
ANDE | 0.905 |
NATI | 0.903 |
DRNA | 0.902 |
10 Most Negative Correlations | |
---|---|
CFV | -0.951 |
AKAM | -0.888 |
BNIXU | -0.882 |
GMII | -0.88 |
TUEM | -0.874 |
EAR | -0.85 |
SHLD | -0.845 |
TRMK | -0.84 |
DTSS | -0.838 |
VIVE | -0.837 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
VYNE Therapeutics Inc. Correlation - Currency/Commodity
VYNE Therapeutics Inc. Financials
Annual | 2023 |
Revenue: | $424 000 |
Gross Profit: | $424 000 (100.00 %) |
EPS: | $-2.77 |
Q4 | 2023 |
Revenue: | $76 000.00 |
Gross Profit: | $76 000.00 (100.00 %) |
EPS: | $-0.200 |
Q3 | 2023 |
Revenue: | $114 000 |
Gross Profit: | $114 000 (100.00 %) |
EPS: | $-2.01 |
Q2 | 2023 |
Revenue: | $135 000 |
Gross Profit: | $135 000 (100.00 %) |
EPS: | $-3.07 |
Financial Reports:
No articles found.
VYNE Therapeutics Inc.
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators